Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

Completed · Phase 4

Conditions studied: Rheumatoid Arthritis

In brief

It is hypothesized that repository corticotropin injection in combination with other biologic agents will be able to provide relief of both rheumatoid arthritis and acute exacerbations of rheumatoid arthritis for patients with disease that had inadequately responded to biologics previously.

Key facts

Study ID

NCT01966718

Run by

Arthritis Treatment Center, Maryland

People needed

8

Starts

2013-10-01

Expected to finish

2015-10-01

Last updated by the study team

2016-08-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Rheumatoid arthritis of at least 2 years duration
• On at least third biologic with a different mechanism of action for at least 12 weeks
• Active disease as defined by at least 6 tender and 6 swollen joints
• Erythrocyte sedimentation rate (ESR) at least 28 mm/hr or C-reactive protein (CRP) at least 1.2 times the upper limit of normal
• Stable dose of disease modifying anti-rheumatic drug (DMARD) and prednisone for at least 4 weeks

You may not qualify if…

• Prior treatment with Acthar Gel
• History of intolerance or allergy to glucocorticoids
• Unstable diabetes
• Active infection

Where it is running

• Arthritis Treatment Center — Frederick, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.